<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PRIMLEV- oxycodone hydrochloride and acetaminophen tablet </strong><br>Akrimax Pharmaceuticals, LLC<br></p></div>
<h1>Primlev</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_fd7fb94a-f521-44e2-a204-5129508e20d8"></a><a name="section-1"></a><p></p>
<h1><span class="Bold">WARNING</span></h1>
</div>
<div class="Warning">
<a name="LINK_fcce500b-6fbd-46f5-b9ee-87b97c0a6686"></a><a name="section-2"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">HEPATOTOXICITY</span></p>
<p>ACETAMINOPHEN HAS BEEN ASSOCIATED WITH CASES OF <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">ACUTE LIVER FAILURE</span>, AT TIMES RESULTING IN LIVER TRANSPLANT AND <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">DEATH</span>. MOST OF THE CASES OF <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">LIVER INJURY</span> ARE ASSOCIATED WITH THE USE OF ACETAMINOPHEN AT DOSES THAT EXCEED 4000 MILLIGRAMS PER DAY, AND OFTEN INVOLVE MORE THAN ONE ACETAMINOPHEN-CONTAINING PRODUCT.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_a6ec4773-9ce1-47d9-a635-5d74205d23d9"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Each tablet, for oral administration, contains oxycodone hydrochloride and acetaminophen in the following strengths:</p>
<p>Oxycodone Hydrochloride, USP …... 5 mg*</p>
<p>Acetaminophen, USP ……………… 300 mg</p>
<p>*5 mg oxycodone HCl is equivalent to 4.4815 mg of oxycodone.</p>
<p>Oxycodone Hydrochloride, USP …... 7.5 mg*</p>
<p>Acetaminophen, USP ……………… 300 mg</p>
<p>*7.5 mg oxycodone HCl is equivalent to 6.7228 mg of oxycodone.</p>
<p>Oxycodone Hydrochloride, USP …... 10 mg*</p>
<p>Acetaminophen, USP ……………… 300 mg</p>
<p>*10 mg oxycodone HCl is equivalent to 8.9637 mg of oxycodone.</p>
<p>All strengths of PRIMLEV<span class="Sup">TM</span> also contain the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, crospovidone, microcrystalline cellulose, povidone, pregelatinized starch, and stearic acid. </p>
<p>In addition, the 5 mg/300 mg strength contains D&amp;C Yellow #10; the 7.5 mg/300 mg strength contains FD&amp;C Red #40 Aluminum Lake; the 10 mg/300 mg strength contains FD&amp;C Yellow #6 Aluminum Lake.</p>
<p>Oxycodone, 14-hydroxydihydrocodeinone, is a semisynthetic opioid analgesic which occurs as a white, odorless, crystalline powder having a saline, bitter taste. The molecular formula for oxycodone hydrochloride is C<span class="Sub">18</span>H<span class="Sub">21</span>NO<span class="Sub">4</span>•HCl and the molecular weight is 351.82. It is derived from the opium alkaloid thebaine, and may be represented by the following structural formula:</p>
<div class="Figure"><img alt="oxycodone chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=94679f29-d63a-41a5-bdda-3aa3fc2db531&amp;name=primlev-1.jpg"></div>
<p>C<span class="Sub">18</span>H<span class="Sub">21</span>NO<span class="Sub">4</span> · HCl MW 351.82 </p>
<p>Acetaminophen, 4'-hydroxyacetanilide, is a non-opiate, non-salicylate analgesic and antipyretic which occurs as a white, odorless, crystalline powder, possessing a slightly bitter taste. The molecular formula for acetaminophen is C<span class="Sub">8</span>H<span class="Sub">9</span>NO<span class="Sub">2 </span>and the molecular weight is 151.16. It may be represented by the following structural formula</p>
<div class="Figure"><img alt="acetaminophen chemical structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=94679f29-d63a-41a5-bdda-3aa3fc2db531&amp;name=primlev-2.jpg"></div>
<p>C<span class="Sub">8</span>H<span class="Sub">9</span>NO<span class="Sub">2</span> MW 151.16 </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_60acf655-dc86-433a-bece-fecc5e943764"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2869c11e-5d78-40da-a408-46b41f4e6a10"></a><a name="section-3.1"></a><p></p>
<h2>Central Nervous System</h2>
<p class="First">Oxycodone is a semisynthetic pure opioid agonist whose principal therapeutic action is <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Other pharmacological effects of oxycodone include anxiolysis, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span> and feelings of relaxation. These effects are mediated by receptors (notably μ and к) in the central nervous system for endogenous opioid-like compounds such as endorphins and enkephalins. Oxycodone produces <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> through direct activity at respiratory centers in the brain stem and depresses the <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> reflex by direct effect on the center of the medulla.</p>
<p>Acetaminophen is a non-opiate, non-salicylate analgesic and antipyretic. The site and mechanism for the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of acetaminophen has not been determined. The antipyretic effect of acetaminophen is accomplished through the inhibition of endogenous pyrogen action on the hypothalamic heat-regulating centers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_451d771d-2257-4490-a93e-94dee529b38e"></a><a name="section-3.2"></a><p></p>
<h2>Gastrointestinal Tract and Other Smooth Muscle</h2>
<p class="First">Oxycodone reduces motility by increasing smooth muscle tone in the stomach and duodenum. In the small intestine, digestion of food is delayed by decreases in propulsive contractions. Other opioid effects include contraction of biliary tract smooth muscle, spasm of the Sphincter of Oddi, increased ureteral and bladder sphincter tone, and a reduction in uterine tone. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_85a3b719-f88b-427d-b250-be1f1ec1eb0d"></a><a name="section-3.3"></a><p></p>
<h2>Cardiovascular System</h2>
<p class="First">Oxycodone may produce a release of histamine and may be associated with <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, and other symptoms, such as <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eyes</span>, and <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="LINK_2864cab6-d404-4941-8714-cf5adca50141"></a><a name="section-3.4"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">Absorption and Distribution</p>
<p>The mean absolute oral bioavailability of oxycodone in cancer patients was reported to be about 87%. Oxycodone has been shown to be 45% bound to human plasma proteins in vitro. The volume of distribution after intravenous administration is 211.9 ± 186.6 L.</p>
<p>Absorption of acetaminophen is rapid and almost complete from the GI tract after oral administration. With overdosage, absorption is complete in 4 hours. Acetaminophen is relatively uniformly distributed throughout most body fluids. Binding of the drug to plasma proteins is variable; only 20% to 50% may be bound at the concentrations encountered during acute <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7ec1403a-0ce6-4db5-b982-3fc7f69299b3"></a><a name="section-3.5"></a><p></p>
<h2>Metabolism and Elimination</h2>
<p class="First">A high portion of oxycodone is N-dealkylated to noroxycodone during first-pass metabolism. Oxymorphone, is formed by the O-demethylation of oxycodone. The metabolism of oxycodone to oxymorphone is catalyzed by CYP2D6. Free and conjugated noroxycodone, free and conjugated oxycodone, and oxymorphone are excreted in human urine following a single oral dose of oxycodone. Approximately 8% to 14% of the dose is excreted as free oxycodone over 24 hours after administration. Following a single, oral dose of oxycodone, the mean ± SD elimination half-life is 3.51 ± 1.43 hours.</p>
<p>Acetaminophen is metabolized in the liver via cytochrome P450 microsomal enzyme. About 80 to 85% of the acetaminophen in the body is conjugated principally with glucuronic acid and to a lesser extent with sulfuric acid and cysteine. After hepatic conjugation, 90 to 100% of the drug is recovered in the urine within  the first day.</p>
<p>About 4% of acetaminophen is metabolized via cytochrome P450 oxidase to a toxic metabolite which is further detoxified by conjugation with glutathione, present in a fixed amount. It is believed that the toxic metabolite NAPQI (N-acetyl-p-benzoquinoneimine, N-acetylimidoquinone) is responsible for <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">liver necrosis</span>. High doses of acetaminophen may deplete the glutathione  stores so that inactivation of the toxic metabolite is decreased. At high doses, the capacity of metabolic pathways for conjugation with glucuronic acid and sulfuric acid may be exceeded, resulting in increased metabolism of acetaminophen by alternate pathways.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_e7bcda38-e1ef-4faf-a5ba-e4dc6d62b597"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">PRIMLEV<span class="Sup">TM</span> (oxycodone and acetaminophen tablets, USP) is indicated for the relief of moderate to moderately severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_fde44639-7983-4615-a552-7b1a168e75db"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">PRIMLEV<span class="Sup">TM</span> should not be administered to patients with known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to oxycodone, acetaminophen, or any other component of this product.</p>
<p>Oxycodone is contraindicated in any situation where opioids are contraindicated including patients with significant <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (in unmonitored settings or the absence of resuscitative equipment) and patients with acute or severe bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or <span class="product-label-link" type="condition" conceptid="4105765" conceptname="Hypercapnia">hypercarbia</span>. Oxycodone is contraindicated in the setting of suspected or known <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_de52d170-4cad-4aa4-9fb5-a3be98fa9d8b"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_8564f152-c4d9-47b3-994a-cb64caf480ae"></a><a name="section-6.1"></a><p></p>
<h2>Misuse, Abuse and Diversion of Opioids</h2>
<p class="First">Oxycodone is an opioid agonist of the morphine-type. Such drugs are sought by drug abusers and people with addiction disorders and are subject to criminal diversion.</p>
<p>Oxycodone can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing PRIMLEV<span class="Sup">TM</span> in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. Concerns about misuse, addiction, and diversion should not prevent the proper management of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>.</p>
<p>Healthcare professionals should contact their State Professional Licensing Board or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product.</p>
<p>Administration of PRIMLEV<span class="Sup">TM</span> should be closely monitored for the following potentially serious adverse reactions and complications:</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_67375d88-d474-4e51-b937-a65d43e5e3a0"></a><a name="section-6.2"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory Depression</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">Respiratory depression</span> is a hazard with the use of oxycodone, one of the active ingredients in PRIMLEV<span class="Sup">TM</span>, as with all opioid agonists. Elderly and debilitated patients are at particular risk for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> as are non-tolerant patients given large initial doses of oxycodone or when oxycodone is given in conjunction with other agents that depress respiration. Oxycodone should be used with extreme caution in patients with acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, chronic obstructive <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">pulmonary disorder</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>), <span class="product-label-link" type="condition" conceptid="4307356" conceptname="Cor pulmonale">cor pulmonale</span>, or preexisting respiratory impairment. In such patients, even usual therapeutic doses of oxycodone may decrease respiratory drive to the point of <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>. In these patients alternative non-opioid analgesics should be considered, and opioids should be employed only under careful medical supervision at the lowest effective dose.</p>
<p>In case of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, a reversal agent such as naloxone hydrochloride may be utilized (see <a href="#LINK_f302ddf2-1c18-4471-ad51-cf20b9d3f89b">OVERDOSAGE</a>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_d54ec1dd-c365-41f5-b91f-f6d5e5a78e0d"></a><a name="section-6.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">Head Injury</span> and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">Increased Intracranial Pressure</span></h2>
<p class="First">The respiratory depressant effects of opioids include <span class="product-label-link" type="condition" conceptid="4135927" conceptname="Carbon dioxide">carbon dioxide</span> retention and secondary elevation of cerebrospinal fluid pressure, and may be markedly exaggerated in the presence of <span class="product-label-link" type="condition" conceptid="375415" conceptname="Injury of head">head injury</span>, other intracranial lesions or a pre-existing increase in intracranial pressure. Oxycodone produces effects on pupillary response and consciousness which may obscure neurologic signs of worsening in patients with head injuries.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_fa842abd-d373-4c69-a981-363aec300036"></a><a name="section-6.4"></a><p></p>
<h2>Hypotensive Effect</h2>
<p class="First">Oxycodone may cause severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> particularly in individuals whose ability to maintain blood pressure has been compromised by a depleted blood volume, or after concurrent administration with drugs which compromise vasomotor tone such as phenothiazines. Oxycodone, like all opioid analgesics of the morphine-type, should be administered with caution to patients in circulatory <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>, since vasodilation produced by the drug may further reduce <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and blood pressure. Oxycodone may produce <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span> in ambulatory patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ae09c98c-a9b6-42d9-9f27-4b158da800d6"></a><a name="section-6.5"></a><p></p>
<h2>Hepatotoxicity</h2>
<p class="First">Acetaminophen has been associated with cases of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span>, at times resulting in liver transplant and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Most of the cases of <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> are associated with the use of acetaminophen at doses that exceed 4000 milligrams per day, and often involve more than one acetaminophen-containing product. The excessive intake of acetaminophen may be intentional to cause self-harm or unintentional as patients attempt to obtain more <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief or unknowingly take other acetaminophen-containing products.</p>
<p>The risk of <span class="product-label-link" type="condition" conceptid="4026032" conceptname="Acute hepatic failure">acute liver failure</span> is higher in individuals with underlying liver disease and in individuals who ingest alcohol while taking acetaminophen.</p>
<p>Instruct patients to look for acetaminophen or APAP on package labels and not to use more than one product that contains acetaminophen. Instruct patients to seek medical attention immediately upon ingestion of more than 4000 milligrams of acetaminophen per day, even if they feel well.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_4d79f870-a8a9-4c3b-aec2-18df6e64d64e"></a><a name="section-6.6"></a><p></p>
<h2>Serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">Skin Reactions</span></h2>
<p class="First">Rarely, acetaminophen may cause serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> such as <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span> (<span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">AGEP</span>), <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span> (SJS), and <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span> (TEN), which can be fatal.  Patients should be informed about the signs of serious <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>, and use of the drug should be discontinued at the first appearance of <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span> or any other sign of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2a17cbf4-6e48-4745-8b82-f49e8f734d35"></a><a name="section-6.7"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>/<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span></h2>
<p class="First">There have been post-marketing reports of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> associated with use of acetaminophen. Clinical signs included <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the face, mouth, and throat, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. There were infrequent reports of life-threatening <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> requiring emergency medical attention. Instruct patients to discontinue PRIMLEV<span class="Sup">TM</span> immediately and seek medical care if they experience these symptoms. Do not prescribe PRIMLEV<span class="Sup">TM</span> for patients with acetaminophen <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_f2bc4484-11f8-4735-b784-4eac308dd650"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="LINK_caece7ea-af50-46b0-8863-505d5aa6b8c4"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Opioid analgesics should be used with caution when combined with CNS depressant drugs, and should be reserved for cases where the benefits of opioid <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> outweigh the known risks of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, altered mental state, and <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3d0a5e07-59ce-4de7-aa61-e14653e4ca70"></a><a name="section-7.2"></a><p></p>
<h2>Acute Abdominal Conditions</h2>
<p class="First">The administration of PRIMLEV<span class="Sup">TM</span> or other opioids may obscure the diagnosis or clinical course in patients with acute abdominal conditions.</p>
<p>PRIMLEV<span class="Sup">TM</span> should be given with caution to patients with <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, elderly or debilitated patients, patients with severe impairment of hepatic, pulmonary, or renal function, <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span>, Addison’s disease,  <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>,  <span class="product-label-link" type="condition" conceptid="195590" conceptname="Urethral stricture">urethral stricture</span>, acute <span class="product-label-link" type="condition" conceptid="4218106" conceptname="Alcoholism">alcoholism</span>, <span class="product-label-link" type="condition" conceptid="377830" conceptname="Alcohol withdrawal delirium">delirium tremens</span>, kyphoscoliosis with <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="4182596" conceptname="Myxedema">myxedema</span>, and toxic <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>.</p>
<p>PRIMLEV<span class="Sup">TM</span> may obscure the diagnosis or clinical course in patients with acute abdominal conditions. Oxycodone may aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> in patients with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsive disorders</span>, and all opioids may induce or aggravate <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in some clinical settings.</p>
<p>Following administration of PRIMLEV<span class="Sup">TM</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> have been reported in patients with a known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to codeine, a compound with a structure similar to morphine and oxycodone. The frequency of this possible cross-sensitivity is unknown.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_e22f79f4-a973-4952-bdd6-184121752075"></a><a name="section-7.3"></a><p></p>
<h2>Interactions with Other CNS Depressants</h2>
<p class="First">Patients receiving other opioid analgesics, general anesthetics, phenothiazines, other tranquilizers, centrally-acting anti-emetics, sedative-hypnotics or other CNS depressants (including alcohol) concomitantly with PRIMLEV<span class="Sup">TM</span> may exhibit an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. When such combined therapy is contemplated, the dose of one or both agents should be reduced.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_027e83c4-8a1a-4644-9041-4a8dcfffd7a6"></a><a name="section-7.4"></a><p></p>
<h2>Interactions With Mixed Agonist/Antagonist Opioid Analgesics</h2>
<p class="First">Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, and butorphanol) should be administered with caution to a patient who has received or is receiving a course of therapy with a pure opioid agonist analgesic such as oxycodone. In this situation, mixed agonist/antagonist analgesics may reduce the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of oxycodone and/or may precipitate withdrawal symptoms in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_18decb48-bc6a-4dea-bbf8-e3d3c7a33489"></a><a name="section-7.5"></a><p></p>
<h2>Ambulatory Surgery and Postoperative Use</h2>
<p class="First">Oxycodone and other morphine-like opioids have been shown to decrease bowel motility. <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">Ileus</span> is a common postoperative complication, especially after intra-abdominal surgery with use of opioid <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>. Caution should be taken to monitor for decreased bowel motility in postoperative patients receiving opioids. Standard supportive therapy should be implemented.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3cd8cdd3-af75-46f7-8e89-4f181a641ff8"></a><a name="section-7.6"></a><p></p>
<h2>Use in Pancreatic/<span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">Biliary Tract Disease</span></h2>
<p class="First">Oxycodone may cause spasm of the Sphincter of Oddi and should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="197917" conceptname="Disorder of biliary tract">biliary tract disease</span>, including <span class="product-label-link" type="condition" conceptid="199074" conceptname="Acute pancreatitis">acute pancreatitis</span>. Opioids like oxycodone may cause increases in the serum amylase level.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1991b812-19d5-4173-9f3a-a5a0cb4723b2"></a><a name="section-7.7"></a><p></p>
<h2>Tolerance and Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">Tolerance is the need for increasing doses of opioids to maintain a defined effect such as <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span> (in the absence of disease progression or other external factors). Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance are not unusual during chronic opioid therapy.</p>
<p>The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, perspiration, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span>, and <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>. Other symptoms also may develop, including: <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">backache</span>, <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">joint pain</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, or <span class="product-label-link" type="condition" conceptid="141693" conceptname="Elevated blood-pressure reading without diagnosis of hypertension">increased blood pressure</span>, <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span>, or heart rate.</p>
<p>In general, opioids should not be abruptly discontinued (see <a href="#LINK_48003434-820c-4c7f-8d2b-7cb2e8268f34">DOSAGE AND ADMINISTRATION</a>: <a href="#LINK_41994796-1a64-4ac6-a7b8-5578ab6a1283">Cessation of Therapy</a>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_568d65f2-5f18-414a-af4b-f013731a33cd"></a><a name="section-7.8"></a><p></p>
<h2>Information for Patients/Caregivers</h2>
<p class="First"><span class="Italics">The following information should be provided to patients receiving PRIMLEV<span class="Sup">TM</span> by their physician, nurse, pharmacist, or caregiver:</span></p>
<ol class="Arabic">
<li>Patients should be aware that PRIMLEV<span class="Sup">TM</span> contains oxycodone, which is a morphine-like substance.</li>
<li>Patients should be instructed to keep PRIMLEV<span class="Sup">TM</span> in a secure place out of the reach of children. In the case of accidental ingestions, emergency medical care should be sought immediately.</li>
<li>When PRIMLEV<span class="Sup">TM</span> is no longer needed, the unused tablets should be destroyed by <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> down the toilet.</li>
<li>Patients should be advised not to adjust the medication dose themselves. Instead, they must consult with their prescribing physician.</li>
<li>Patients should be advised that PRIMLEV<span class="Sup">TM</span> may impair mental and/or physical ability required or the performance of potentially hazardous tasks (e.g., driving, operating heavy machinery).</li>
<li>Patients should not combine PRIMLEV<span class="Sup">TM</span> with alcohol, opioid analgesics, tranquilizers, sedatives, or other CNS depressants unless under the recommendation and guidance of a physician. When co-administered with another CNS depressant, PRIMLEV<span class="Sup">TM</span> can cause dangerous additive central nervous system or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, which can result in serious injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</li>
<li>The safe use of PRIMLEV<span class="Sup">TM</span> during pregnancy has not been established; thus, women who are planning to become pregnant or are pregnant should consult with their physician before taking PRIMLEV<span class="Sup">TM</span>.</li>
<li>Nursing mothers should consult with their physicians about whether to discontinue nursing or discontinue PRIMLEV<span class="Sup">TM</span> because of the potential for serious adverse reactions to nursing infants.</li>
<li>Patients who are treated with PRIMLEV<span class="Sup">TM</span> for more than a few weeks should be advised not to abruptly discontinue the medication. Patients should consult with their physician for a gradual discontinuation dose schedule to taper off the medication.</li>
<li>Patients should be advised that PRIMLEV<span class="Sup">TM</span> is a potential drug of abuse. They should protect it from <span class="product-label-link" type="condition" conceptid="4087298" conceptname="Theft">theft</span>, and it should never be given to anyone other than the individual for whom it was prescribed.</li>
<li>Do not take PRIMLEV<span class="Sup">TM</span> if you are allergic to any of its ingredients.</li>
<li>If you develop signs of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> such as a <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, stop taking PRIMLEV<span class="Sup">TM</span> and contact your healthcare provider immediately.</li>
<li>Do not take more than 4000 milligrams of acetaminophen per day. Call your doctor if you took more than the recommended dose.</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="LINK_62323570-1fc7-4de7-8b89-a40bcffdeda4"></a><a name="section-7.9"></a><p></p>
<h2>Laboratory Tests</h2>
<p class="First">Although oxycodone may cross-react with some drug urine tests, no available studies were found which determined the duration of detectability of oxycodone in <span class="product-label-link" type="condition" conceptid="4215138" conceptname="Drug screening test">urine drug screens</span>. However, based on pharmacokinetic data, the approximate duration of detectability for a single dose of oxycodone is roughly estimated to be one to two days following drug exposure.</p>
<p>Urine testing for opiates may be performed to determine illicit drug use and for medical reasons such as evaluation of patients with altered states of consciousness or monitoring efficacy of drug rehabilitation efforts. The preliminary identification of opiates in urine involves the use of an immunoassay screening and thin-layer chromatography (TLC). Gas chromatography/<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> spectrometry (GC/MS) may be utilized as a third-stage identification step in the medical investigational sequence for opiate testing after immunoassay and TLC. The identities of 6-keto opiates (e.g., oxycodone) can further be differentiated by the analysis of their methoxime-trimethylsilyl (MO-TMS) derivative.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b766fbd9-66d4-4145-b0c9-df9c83b9afc6"></a><a name="section-7.10"></a><p></p>
<h2>Drug/Drug Interactions with Oxycodone</h2>
<p class="First">Opioid analgesics may enhance the neuromuscular-blocking action of skeletal muscle relaxants and produce an increase in the degree of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>.</p>
<p>Patients receiving CNS depressants such as other opioid analgesics, general anesthetics, phenothiazines, other tranquilizers, centrally-acting anti-emetics, sedative-hypnotics or other CNS depressants (including alcohol) concomitantly with PRIMLEV<span class="Sup">TM</span> may exhibit an additive <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>. When such combined therapy is contemplated, the dose of one or both agents should be reduced. The concurrent use of anticholinergics with opioids may produce <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span>.</p>
<p>Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, naltrexone, and butorphanol) should be administered with caution to a patient who has received or is receiving a pure opioid agonist such as oxycodone. These agonist/antagonist analgesics may reduce the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of oxycodone or may precipitate withdrawal symptoms.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_32128580-ee0c-45b9-a2d8-ee7e03ba56ac"></a><a name="section-7.11"></a><p></p>
<h2>Drug/Drug Interactions with Acetaminophen</h2>
<p class="First">Alcohol, ethyl: Hepatotoxicity has occurred in chronic alcoholics following various dose levels (moderate to excessive) of acetaminophen.</p>
<p>Anticholinergics: The onset of acetaminophen effect may be delayed or decreased slightly, but the ultimate pharmacological effect is not significantly affected by anticholinergics.</p>
<p>Oral Contraceptives: Increase in glucuronidation resulting in increased plasma clearance and a decreased half-life of acetaminophen.</p>
<p>Charcoal (activated): Reduces acetaminophen absorption when administered as soon as possible after <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>.</p>
<p>Beta Blockers (Propranolol): Propranolol appears to inhibit the enzyme systems responsible for the glucuronidation and oxidation of acetaminophen. Therefore, the pharmacologic effects of acetaminophen may be increased.</p>
<p>Loop diuretics: The effects of the loop diuretic may be decreased because acetaminophen may decrease renal prostaglandin excretion and decrease plasma renin activity.</p>
<p>Lamotrigine: Serum lamotrigine concentrations may be reduced, producing a decrease in therapeutic effects.</p>
<p>Probenecid: Probenecid may increase the therapeutic effectiveness of acetaminophen slightly.</p>
<p>Zidovudine: The pharmacologic effects of zidovudine may be decreased because of enhanced non-hepatic or renal clearance of zidovudine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_c4fb888f-a931-4cf8-9198-297b1e201d2e"></a><a name="section-7.12"></a><p></p>
<h2>Drug/Laboratory Test Interactions</h2>
<p class="First">Depending on the sensitivity/specificity and the test methodology, the individual components of PRIMLEV<span class="Sup">TM</span> may cross-react with assays used in the preliminary detection of cocaine (primary urinary metabolite, benzoylecgonine) or marijuana (cannabinoids) in human urine. A more specific alternate chemical method must be used in order to obtain a confirmed analytical result. The preferred confirmatory method is gas chromatography/<span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> spectrometry (GC/MS). Moreover, clinical considerations and professional judgment should be applied to any drug-of-abuse test result, particularly when preliminary positive results are used.</p>
<p>Acetaminophen may interfere with home blood glucose measurement systems; decreases of &gt; 20% in mean glucose values may be noted. This effect appears to be drug, concentration and system dependent.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="LINK_67d24dfb-d54c-4c22-960e-b92ea42884bc"></a><a name="section-7.13"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7c103ff0-98c8-4472-8fbc-460e83819c3a"></a><a name="section-7.13.1"></a><p></p>
<h3>Carcinogenesis</h3>
<p class="First">Animal studies to evaluate the carcinogenic potential of oxycodone and acetaminophen have not been performed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7a51b6fb-eb80-47c8-8bcc-209bd9d462a6"></a><a name="section-7.13.2"></a><p></p>
<h3>Mutagenesis</h3>
<p class="First">The combination of oxycodone and acetaminophen has not been evaluated for mutagenicity. Oxycodone alone was negative in a bacterial reverse mutation assay (Ames), an <span class="Italics"> in</span><span class="Italics"> vitro</span> chromosome aberration assay with human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> without metabolic activation and an <span class="Italics"> in vivo</span> mouse micronucleus assay. Oxycodone was clastogenic in the human lymphocyte chromosomal assay in the presence of metabolic activation and in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay with or without metabolic activation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3f15fd0e-c7e3-4ae1-a153-6a0c57ab5bdc"></a><a name="section-7.13.3"></a><p></p>
<h3>Fertility</h3>
<p class="First">Animal studies to evaluate the effects of oxycodone on fertility have not been performed.</p>
</div>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="LINK_8e064888-9281-456d-af70-6587303bfaef"></a><a name="section-7.14"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="LINK_34423466-1b49-468c-a82c-4190d271270c"></a><a name="section-7.14.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_3ef137dc-568a-4391-9bd0-0074687dad04"></a><a name="section-7.14.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Animal reproductive studies have not been conducted with PRIMLEV<span class="Sup">TM</span>. It is also not known whether PRIMLEV<span class="Sup">TM</span> can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. PRIMLEV<span class="Sup">TM</span> should not be given to a pregnant woman unless in the judgment of the physician, the potential benefits outweigh the possible hazards.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="LINK_2a2d3604-3375-4eb6-b458-18f7e5929e65"></a><a name="section-7.14.2"></a><p></p>
<h3>Nonteratogenic Effects</h3>
<p class="First">Opioids can cross the placental barrier and have the potential to cause <span class="product-label-link" type="condition" conceptid="4318857" conceptname="Neonatal respiratory depression">neonatal respiratory depression</span>. Opioid use during pregnancy may result in a physically drug-dependent fetus. After birth, the neonate may suffer severe withdrawal symptoms.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="LINK_f536bcf9-c9af-4c88-9f39-4cbca36a03b8"></a><a name="section-7.15"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">PRIMLEV<span class="Sup">TM</span> is not recommended for use in women during and immediately prior to labor and delivery due to its potential effects on respiratory function in the newborn.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="LINK_e1d68b02-5987-41be-864d-3a33ca7360a2"></a><a name="section-7.16"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Ordinarily, nursing should not be undertaken while a patient is receiving PRIMLEV<span class="Sup">TM</span> because of the possibility of sedation and/or <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> in the infant. Oxycodone is excreted in breast milk in low concentrations, and there have been rare reports of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> in babies of nursing mothers taking an oxycodone/acetaminophen product. Acetaminophen is also excreted in breast milk in low concentrations.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="LINK_dcbad816-cf9b-4079-b81b-1cedf26e7b03"></a><a name="section-7.17"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="LINK_c7fcb1de-f4b7-4c47-be9f-dc228dc3c596"></a><a name="section-7.18"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Special precaution should be given when determining the dosing amount and frequency of PRIMLEV<span class="Sup">TM</span> for geriatric patients, since clearance of oxycodone may be slightly reduced in this patient population when compared to younger patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_ef11da72-8ca8-4776-9a8e-27875c73ca96"></a><a name="section-7.19"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<p class="First">In a pharmacokinetic study of oxycodone in patients with end-stage liver disease, oxycodone plasma clearance decreased and the elimination half-life increased. Care should be exercised when oxycodone is used in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_16f333c3-f1dc-45fd-982d-243d081f72ff"></a><a name="section-7.20"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In a study of patients with end stage <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, mean elimination half-life was prolonged in uremic patients due to increased volume of distribution and reduced clearance. Oxycodone should be used with caution in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_f16a4123-1da3-4c6d-95c9-54987acc0e4d"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Serious adverse reactions that may be associated with PRIMLEV<span class="Sup">TM</span> use include <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="317109" conceptname="Respiratory arrest">respiratory arrest</span>, circulatory <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, and <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> (see <a href="#LINK_f302ddf2-1c18-4471-ad51-cf20b9d3f89b">OVERDOSAGE</a>).</p>
<p>The most frequently observed non-serious adverse reactions include <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or sedation, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. These effects seem to be more prominent in ambulatory than in nonambulatory patients, and some of these adverse reactions may be alleviated if the patient lies down. Other adverse reactions include <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="4148767" conceptname="Dysphoric mood">dysphoria</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity reactions</span> may include: <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Skin eruptions</span>, urticarial, erythematous <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span>. Hematologic reactions may include: <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>. Rare cases of <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> has likewise been associated with acetaminophen use. In high doses, the most serious adverse effect is a dose-dependent, potentially fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span>. <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">Renal tubular necrosis</span> and <span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">hypoglycemic coma</span> also may occur.</p>
<p>Other adverse reactions obtained from postmarketing experiences with PRIMLEV<span class="Sup">TM</span> are listed by organ system and in decreasing order of severity and/or frequency as follows:</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6f162671-30ed-49bd-aec2-ba6ffdcad9a6"></a><a name="section-8.1"></a><p></p>
<h2>Body as a Whole</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reaction</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>, <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">malaise</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">thirst</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, non-accidental <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6b10c5dd-72b1-45c6-a3a4-23f67bc9c4a8"></a><a name="section-8.2"></a><p></p>
<h2>Cardiovascular</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">orthostatic hypotension</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">dysrhythmias</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_454b5e3b-33b7-4900-a13b-80eb33b9cc8d"></a><a name="section-8.3"></a><p></p>
<h2>Central and Peripheral Nervous System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">Stupor</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paraesthesia</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">hypoaesthesia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="438409" conceptname="Attention deficit hyperactivity disorder">mental impairment</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="376690" conceptname="Cerebral edema">cerebral edema</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_9bebe33c-a15e-4d13-b192-510daa483727"></a><a name="section-8.4"></a><p></p>
<h2>Fluid and Electrolyte</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">Dehydration</span>, <span class="product-label-link" type="condition" conceptid="434610" conceptname="Hyperkalemia">hyperkalemia</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, <span class="product-label-link" type="condition" conceptid="4006309" conceptname="Respiratory alkalosis">respiratory alkalosis</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_87a10295-f13c-464f-86ad-eb36cf273fa3"></a><a name="section-8.5"></a><p></p>
<h2>Gastrointestinal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste disturbances</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating increased</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">flatulence</span>, gastro-intestinal disorder, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">ileus</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1fcfc2a6-5355-47b7-bf87-7e04d9311fe1"></a><a name="section-8.6"></a><p></p>
<h2>Hepatic</h2>
<p class="First">Transient elevations of hepatic enzymes, increase in bilirubin, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span>, <span class="product-label-link" type="condition" conceptid="137977" conceptname="Jaundice">jaundice</span>, hepatotoxicity, hepatic disorder</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b9e4694b-78b4-4b55-b274-a1c8075e65cc"></a><a name="section-8.7"></a><p></p>
<h2>Hearing and Vestibular</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing loss</span>,  <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_6cd3efa8-3b43-4d34-914d-3e4a6d4b38f7"></a><a name="section-8.8"></a><p></p>
<h2>Hematologic</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_1383359f-db7c-4875-863d-3fe1b486e184"></a><a name="section-8.9"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Acute anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_d672a6b6-b894-4e13-b3d5-627db481dfad"></a><a name="section-8.10"></a><p></p>
<h2>Metabolic and Nutritional</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, <span class="product-label-link" type="condition" conceptid="438730" conceptname="Alkalosis">alkalosis</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a0609a25-8593-4ee8-aa26-a157eea5d047"></a><a name="section-8.11"></a><p></p>
<h2>Musculoskeletal</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>, <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_17035740-3c72-4a97-86f5-b366985cc548"></a><a name="section-8.12"></a><p></p>
<h2>Ocular</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435279" conceptname="Tonic pupillary reaction">Miosis</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">red eye</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2193aac4-1d46-4e83-8e58-f21e0087474d"></a><a name="section-8.13"></a><p></p>
<h2>Psychiatric</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug dependence</span>, drug abuse, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">depressed level of consciousness</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a13c5279-0f89-4699-bd44-77c6a5126c53"></a><a name="section-8.14"></a><p></p>
<h2>Respiratory System</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperpnea</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="317376" conceptname="Tachypnea">tachypnea</span>, <span class="product-label-link" type="condition" conceptid="4239038" conceptname="Pulmonary aspiration">aspiration</span>, <span class="product-label-link" type="condition" conceptid="312603" conceptname="Hypoventilation">hypoventilation</span>, <span class="product-label-link" type="condition" conceptid="22350" conceptname="Edema of larynx">laryngeal edema</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_411cb56c-de21-4027-b42e-501b0089bd31"></a><a name="section-8.15"></a><p></p>
<h2>Skin and Appendages</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_abe30e76-b9c3-4e38-8fce-97937b4c1e45"></a><a name="section-8.16"></a><p></p>
<h2>Urogenital</h2>
<p class="First">Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, papillary <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span>, <span class="product-label-link" type="condition" conceptid="75650" conceptname="Proteinuria">proteinuria</span>, <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span> and failure, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="LINK_7589ac92-6a18-4971-8b0f-61cc613dde21"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">PRIMLEV<span class="Sup">TM</span> is a Schedule II controlled substance. Oxycodone is a mu-agonist opioid with an abuse liability similar to morphine. Oxycodone, like morphine and other opioids used in <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesia</span>, can be abused and is subject to criminal diversion.</p>
<p><span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is defined as an abnormal, compulsive use, use for non-medical purposes of a substance despite physical, psychological, occupational or interpersonal difficulties resulting from such use, and continued use despite harm or risk of harm. <span class="product-label-link" type="condition" conceptid="440069" conceptname="Drug dependence">Drug addiction</span> is a treatable disease, utilizing a multi-disciplinary approach, but relapse is common. Opioid addiction is relatively rare in patients with <span class="product-label-link" type="condition" conceptid="436096" conceptname="Chronic pain">chronic pain</span> but may be more common in individuals who have a past history of alcohol or <span class="product-label-link" type="condition" conceptid="4279309" conceptname="Substance abuse">substance abuse</span> or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>. Pseudoaddiction refers to <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> relief seeking behavior of patients whose <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is poorly managed. It is considered an iatrogenic effect of ineffective <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> management. The health care provider must assess continuously the psychological and clinical condition of a <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> patient in order to distinguish addiction from pseudoaddiction and thus, be able to treat the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> adequately.</p>
<p>Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> on a prescribed medication does not signify addiction. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> involves the occurrence of a withdrawal syndrome when there is sudden reduction or cessation in drug use or if an opiate antagonist is administered. Physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> can be detected after a few days of opioid therapy. However, clinically significant physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> is only seen after several weeks of relatively high dosage therapy. In this case, abrupt discontinuation of opioid may result in a withdrawal syndrome. If the discontinuation of opioids is therapeutically indicated, gradual tapering of the drug over a 2-week period will prevent withdrawal symptoms. The severity of the withdrawal syndrome depends primarily on the daily dosage of the opioid, the duration of therapy and medical status of the individual.</p>
<p>The withdrawal syndrome of oxycodone is similar to that of morphine. This syndrome is characterized by <span class="product-label-link" type="condition" conceptid="4089239" conceptname="Yawning">yawning</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, increased heart rate and blood pressure, <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restlessness</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle aches</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span> alternating with <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">salivation</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, severe <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="435553" conceptname="Epiphora">lacrimation</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, <span class="product-label-link" type="condition" conceptid="4224957" conceptname="Piloerection">piloerection</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal cramps</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, and pronounced <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
<p>"Drug-seeking" behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated "loss" of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). "Doctor Shopping" to obtain additional prescriptions is common among drug abusers and people suffering from untreated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>.</p>
<p>Abuse and addiction are separate and distinct from physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> in all addicts. In addition, abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Oxycodone, like other opioids, has been diverted for non-medical use. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.</p>
<p>Proper assessment of the patient, proper prescribing practices, periodic reevaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.</p>
<p>Like other opioid medications, PRIMLEV<span class="Sup">TM</span> is subject to the Federal Controlled Substances Act. After chronic use, PRIMLEV<span class="Sup">TM</span> should not be discontinued abruptly when it is thought that the patient has become physically dependent on oxycodone.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_a862d80b-8ebb-4d6d-adbc-7de4aeb71402"></a><a name="section-9.1"></a><p></p>
<h2>Interactions with Alcohol and Drugs of Abuse</h2>
<p class="First">Oxycodone may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="LINK_f302ddf2-1c18-4471-ad51-cf20b9d3f89b"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Following an acute overdosage, toxicity may result from the oxycodone or the acetaminophen.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_f43c6878-2582-4f06-872a-e99719a2ddeb"></a><a name="section-10.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">Toxicity from <span class="Italics">oxycodone</span> <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> includes the opioid triad of: pinpoint pupils, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of respiration, and <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span>.  Serious overdosage with oxycodone is characterized by <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> (a decrease in <span class="product-label-link" type="condition" conceptid="4313591" conceptname="Respiratory rate">respiratory rate</span> and/or tidal volume, Cheyne-Stokes respiration, <span class="product-label-link" type="condition" conceptid="438555" conceptname="Cyanosis">cyanosis</span>), extreme <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> progressing to <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span> or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, skeletal muscle <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">flaccidity</span>, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> and <span class="product-label-link" type="condition" conceptid="4308436" conceptname="Cold sweat">clammy</span> skin, and sometimes <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span> and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In severe overdosage, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> may occur.</p>
<p>In <span class="Italics">acetaminophen</span> overdosage: dose-dependent potentially fatal <span class="product-label-link" type="condition" conceptid="4337543" conceptname="Hepatic necrosis">hepatic necrosis</span> is the most serious adverse effect. <span class="product-label-link" type="condition" conceptid="444044" conceptname="Acute tubular necrosis">Renal tubular necrosis</span>, <span class="product-label-link" type="condition" conceptid="380688" conceptname="Hypoglycemic coma">hypoglycemic coma</span>, and coagulation defects may also occur. Early symptoms following a potentially hepatotoxic <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> may include: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">diaphoresis</span>, and <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">general malaise</span>. Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_7b7f3ccb-0c54-4ed8-bd65-0a71f78b1c74"></a><a name="section-10.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">A single or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdose</span> with oxycodone and acetaminophen is a potentially lethal polydrug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, and consultation with a regional poison control center is recommended.  Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption.  Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated.  Assisted or controlled ventilation should also be considered.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_bc59f915-a77d-4a73-8c94-f258cdddfc8b"></a><a name="section-10.2.1"></a><p></p>
<h3>Oxycodone</h3>
<p class="First">Primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation. The narcotic antagonist naloxone hydrochloride is a specific antidote against <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> which may result from overdosage or unusual sensitivity to narcotics, including oxycodone. Since the duration of action of oxycodone may exceed that of the antagonist, the patient should be kept under continued surveillance, and repeated doses of the antagonist should be administered as needed to maintain adequate respiration.  A narcotic antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_2ad8dadf-de9f-47c2-9611-b2b273691d61"></a><a name="section-10.2.2"></a><p></p>
<h3>Acetaminophen</h3>
<p class="First">Gastric decontamination with activated charcoal should be administered just prior to N-acetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation.  Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading.  To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">liver injury</span> is suspected.  Intravenous NAC may be administered when circumstances preclude oral administration.</p>
<p>Vigorous supportive therapy is required in severe <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.  Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_48003434-820c-4c7f-8d2b-7cb2e8268f34"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Dosage should be adjusted according to the severity of the <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and the response of the patient. It may occasionally be necessary to exceed the usual dosage recommended below in cases of more severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or in those patients who have become tolerant to the <span class="product-label-link" type="condition" conceptid="4242687" conceptname="No sensitivity to pain">analgesic effect</span> of opioids. If <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> is constant, the opioid analgesic should be given at regular intervals on an around-the-clock schedule. PRIMLEV<span class="Sup">TM</span> is given orally. </p>
<p>The usual adult dosage of PRIMLEV<span class="Sup">TM</span> is as follows. The total daily dose of acetaminophen should not exceed 4 grams.</p>
<table>
<col width="1px">
<col width="1px">
<col width="23%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Toprule" valign="top"> <p class="First">Strength</p>
</td>
<td class="Botrule Lrule Toprule" valign="top"> <p class="First">Usual Adult Dose</p>
</td>
<td class="Botrule Lrule Rrule Toprule" align="center" valign="top"> <p class="First"> Maximal Daily Dose </p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"> <p class="First">5 mg/300 mg</p>
</td>
<td class="Botrule Lrule" valign="top"> <p class="First">One Tablet every 6 hours as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"> <p class="First">12 Tablets</p>
</td>
</tr>
<tr>
<td class="Botrule Lrule" valign="top"> <p class="First">7.5 mg/300 mg</p>
</td>
<td class="Botrule Lrule" valign="top"> <p class="First">One Tablet every 6 hours as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"> <p class="First"> 8 Tablets</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule" valign="top"> <p class="First">10 mg/300 mg</p>
</td>
<td class="Botrule Lrule" valign="top"> <p class="First">One Tablet every 6 hours as needed for <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></p>
</td>
<td class="Botrule Lrule Rrule" align="center" valign="top"> <p class="First"> 6 Tablets</p>
</td>
</tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_41994796-1a64-4ac6-a7b8-5578ab6a1283"></a><a name="section-11.1"></a><p></p>
<h2>Cessation of Therapy</h2>
<p class="First">In patients treated with PRIMLEV<span class="Sup">TM</span> for more than a few weeks who no longer require therapy, doses should be tapered gradually to prevent signs and symptoms of withdrawal in the physically dependent patient.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_feb92c00-95fb-4458-b0b6-a04f4da2bcce"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">PRIMLEV<span class="Sup">TM</span> is supplied as follows:</p>
<p><span class="Bold">PRIMLEV<span class="Sup">TM</span> 5 mg/300 mg</span></p>
<p>Yellow, capsule-shaped, convex face tablets, debossed "A" score "P" on one side and "681" on the other side.</p>
<p>Bottles of 30 tablets NDC# 24090-681-85</p>
<p>Bottles of 100 tablets NDC# 24090-681-88</p>
<p><span class="Bold">PRIMLEV<span class="Sup">TM</span> 7.5 mg/300 mg</span></p>
<p>Red, capsule-shaped, flat face, beveled edge tablets, debossed "A P" on one side and "682" on the other side.</p>
<p>Bottles of 30 tablets NDC# 24090-682-85</p>
<p>Bottles of 100 tablets NDC# 24090-682-88</p>
<p><span class="Bold">PRIMLEV<span class="Sup">TM</span> 10 mg/300 mg</span></p>
<p>Orange, oval-shaped, convex face tablets, debossed "A P" on one side and "683" on the other side.</p>
<p>Bottles of 30 tablets NDC# 24090-683-85</p>
<p>Bottles of 100 tablets NDC# 24090-683-88</p>
<p>Store at 20° to 25°C (68° to 77°F). [see USP Controlled Room Temperature].</p>
<p>Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).</p>
<p>DEA Order Form Required. </p>
<p>For further product information, please visit www.akrimax.com or call our medical communications department toll-free at 1-888-383-1733.</p>
<p>Manufactured for Akrimax Pharmaceuticals, LLC, Cranford, NJ 07016</p>
<p>By MIKART, INC., Atlanta, GA 30318</p>
<p>Marketed and Distributed by:</p>
<p>Akrimax Pharmaceuticals, LLC</p>
<p>Cranford, NJ 07016</p>
<p>368F104</p>
<p>Code 1143A00</p>
<p>Rev. 10/13</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_35753a75-b9f8-41e3-b715-8a0e66e8d492"></a><a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC:24090-681-79        100 unit dose tablets<br>PRIMLEV<br>Oxycodone HCI/Acetaminophen<br>5 mg / 300 mg</span></p>
<p><span class="Bold"><img alt="NDC:24090-681-79 100 unit dose tablets PRIMLEV Oxycodone HCI/Acetaminophen 10 mg / 300 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=94679f29-d63a-41a5-bdda-3aa3fc2db531&amp;name=primlev-3.jpg"></span></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_93105f2f-47da-479f-b210-ad60b2df8541"></a><a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL</h1>
<p class="First"><span class="Bold">NDC:24090-683-79        100 unit dose tablets<br>PRIMLEV<br>Oxycodone HCI/Acetaminophen<br>10 mg / 300 mg</span></p>
<p><span class="Bold"><img alt="NDC:24090-683-79 100 unit dose tablets PRIMLEV Oxycodone HCI/Acetaminophen 10 mg / 300 mg" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=94679f29-d63a-41a5-bdda-3aa3fc2db531&amp;name=primlev-4.jpg"></span></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRIMLEV 		
					</strong><br><span class="contentTableReg">oxycodone and acetaminophen tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24090-681</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OXYCODONE HYDROCHLORIDE</strong> (OXYCODONE) </td>
<td class="formItem">OXYCODONE HYDROCHLORIDE</td>
<td class="formItem">5 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ACETAMINOPHEN</strong> (ACETAMINOPHEN) </td>
<td class="formItem">ACETAMINOPHEN</td>
<td class="formItem">300 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>D&amp;C YELLOW NO. 10</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">CAPSULE (convex face) </td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AP;681</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24090-681-79</td>
<td class="formItem">100  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24090-681-71</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040608</td>
<td class="formItem">03/02/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PRIMLEV 		
					</strong><br><span class="contentTableReg">oxycodone and acetaminophen tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:24090-683</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">CII    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>OXYCODONE HYDROCHLORIDE</strong> (OXYCODONE) </td>
<td class="formItem">OXYCODONE HYDROCHLORIDE</td>
<td class="formItem">10 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>ACETAMINOPHEN</strong> (ACETAMINOPHEN) </td>
<td class="formItem">ACETAMINOPHEN</td>
<td class="formItem">300 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SILICON DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSPOVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C YELLOW NO. 6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POVIDONES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STEARIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">ORANGE</td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (convex face) </td>
<td class="formLabel">Size</td>
<td class="formItem">15mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AP;683</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24090-683-79</td>
<td class="formItem">100  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:24090-683-71</td>
<td class="formItem">1  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA040608</td>
<td class="formItem">03/02/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Akrimax Pharmaceuticals, LLC
							(804790124)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8a79e9de-e9fb-4767-b513-fe8ae827bc35</div>
<div>Set id: 94679f29-d63a-41a5-bdda-3aa3fc2db531</div>
<div>Version: 1</div>
<div>Effective Time: 20150227</div>
</div>
</div> <div class="DistributorName">Akrimax Pharmaceuticals, LLC</div></p>
</body></html>
